Savara Inc.
SVRA · Nasdaq · United States
Share price · SVRA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SVRA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+5.4%
Nothing announced by SVRA that day or the session before.
- 6 Nov 2026+10.3%
Nothing announced by SVRA that day or the session before.
- 26 Oct 2026+7.1%
Nothing announced by SVRA that day or the session before.
- 23 Oct 2026-7.0%
Nothing announced by SVRA that day or the session before.
- 7 Oct 2026+4.9%
Nothing announced by SVRA that day or the session before.
- 2 Oct 2026-4.7%
Nothing announced by SVRA that day or the session before.
- 8 Sep 2026+3.0%
Nothing announced by SVRA that day or the session before.
- 13 Aug 2026-7.5%
Nothing announced by SVRA that day or the session before.
- 10 Jun 2026+3.2%
Nothing announced by SVRA that day or the session before.
- 30 Apr 2026+8.0%
Nothing announced by SVRA that day or the session before.
Share of unusual movement by asset
For each asset, the share of SVRA's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
molgramostimevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 2% |
| Sessions with no dated event | — | 97% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GM-CSF receptor (agonist)Protein / enzyme therapeutic | Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $25M | $30M+ $100M short-term inv. | $43M-$42M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $22M | $42M+ $131M short-term inv. | $40M-$30M operating cash flow | report ↗ |
| 2026-Q1 | — | $23M | $39M+ $164M short-term inv. | $37M-$33M operating cash flow | report ↗ |
| 2025-Q3 | — | $21M | $16M+ $108M short-term inv. | $30M-$23M operating cash flow | report ↗ |
| 2025-Q2 | — | $21M | $17M+ $129M short-term inv. | $30M-$26M operating cash flow | report ↗ |
| 2025-Q1 | — | $19M | $20M+ $153M short-term inv. | $27M-$27M operating cash flow | report ↗ |
| 2024-Q3 | — | $20M | $21M+ $198M short-term inv. | $24M-$23M operating cash flow | report ↗ |
| 2024-Q2 | — | $18M | $24M+ $98M short-term inv. | $22M-$22M operating cash flow | report ↗ |
| 2024-Q1 | — | $17M | $17M+ $126M short-term inv. | $20M-$21M operating cash flow | report ↗ |
| 2023-Q3 | — | $14M | $28M+ $141M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2023-Q2 | — | $8.9M | $23M+ $82M short-term inv. | $11M-$10M operating cash flow | report ↗ |
| 2023-Q1 | — | $8.7M | $34M+ $81M short-term inv. | $11M-$12M operating cash flow | report ↗ |
| 2022-Q3 | — | $8.2M | $120M+ $14M short-term inv. | $10M-$8.2M operating cash flow | report ↗ |
| 2022-Q2 | — | $6.4M | $95M+ $47M short-term inv. | $9.2M-$9.3M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.7M | $79M+ $73M short-term inv. | $8.3M-$8.4M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $6.5M | $45M+ $126M short-term inv. | $11M-$8.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $81M | $33M+ $203M short-term inv. | $30M-$101M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $78M | $15M+ $181M short-term inv. | $24M-$89M operating cash flow | report ↗ |
| 2023-FY | — | $44M | $27M+ $136M short-term inv. | $14M-$51M operating cash flow | report ↗ |
| 2022-FY | — | $28M | $52M+ $74M short-term inv. | $9.5M-$35M operating cash flow | report ↗ |
| 2021-FY | — | $29M | $34M+ $127M short-term inv. | $11M-$40M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-24 | Parker Braden C. · Chief Commercial Officer | Tax withholding | 29,323 | $5.07 | $149K | Form 4 |
| 2026-07-15 | Lutz Robert Matthew · Chief Fin. & Operating Officer | Award / grant | 35,000 | — | — | Form 4 |
| 2026-07-15 | Lutz Robert Matthew · Chief Fin. & Operating Officer | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-06-22 | Lowrance David L · Chief Financial Officer | Option exercise | 75,000 | $1.59 | $119K | Form 4 |
| 2026-06-22 | Lowrance David L · Chief Financial Officer | Tax withholding | 21,682 | $5.50 | $119K | Form 4 |
| 2026-06-22 | Lowrance David L · Chief Financial Officer | Option exercise | 129,350 | $1.23 | $159K | Form 4 |
| 2026-06-22 | Lowrance David L · Chief Financial Officer | Tax withholding | 28,928 | $5.50 | $159K | Form 4 |
| 2026-06-22 | Lowrance David L · Chief Financial Officer | Option exercise | 56,937 | $1.11 | $63K | Form 4 |